Status:
UNKNOWN
Intelligent Follow-up of Neonatal Jaundice Based on Early Indicators and Internet Communications
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University
Collaborating Sponsors:
The Children's Hospital of Zhejiang University School of Medicine
Jiaxing University Affiliated Women and Children Hospital
Conditions:
Hyperbilirubinemia, Neonatal
Eligibility:
All Genders
12-7 years
Phase:
NA
Brief Summary
In this prospective multi-center randomized clinical trial, a new follow-up strategy for neonatal jaundice after discharge will be evaluated. It is based on current risk factors of neonatal hyperbilir...
Detailed Description
The eligible newborns will be randomized into two groups: the study group (innovative strategy) and the controlled group (traditional strategy). The innovative strategy included the ETCOc measurement...
Eligibility Criteria
Inclusion
- gestational age between 35(+0)\~41(+6)
- birth weight ≥ 2500 g
- ethics approval obtained
- parental consent obtained
Exclusion
- severe perinatal asphyxia
- infectious diseases
- persistent need for respiratory support
- major congenital malformation
- inborn errors of metabolism
- pathological neonatal hyperbilirubinemia due to the defects of red blood cell membrane and erythrocyte enzyme
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT05365984
Start Date
May 1 2022
End Date
December 1 2024
Last Update
May 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.